Fortrea Reports Second Quarter 2024 Results
Fortrea (Nasdaq: FTRE) reported its Q2 2024 financial results, showing a revenue of $662.4 million and a GAAP net loss of $(99.3) million. The company's adjusted EBITDA was $55.2 million, with a book-to-bill ratio of 0.96x. Fortrea completed divestitures of Endpoint Clinical and Patient Access businesses, reducing debt by $504 million. The company revised its full-year guidance, projecting revenue between $2,700 million to $2,750 million and adjusted EBITDA of $220 million to $240 million. CEO Tom Pike expressed confidence in the company's direction despite challenges, citing progress with customers and important new opportunities.
Fortrea (Nasdaq: FTRE) ha riportato i risultati finanziari del secondo trimestre del 2024, segnalando un fatturato di 662,4 milioni di dollari e una perdita netta GAAP di 99,3 milioni di dollari. L'EBITDA rettificato dell'azienda è stato di 55,2 milioni di dollari, con un rapporto book-to-bill di 0,96x. Fortrea ha completato la dismissione delle attività Endpoint Clinical e Patient Access, riducendo il debito di 504 milioni di dollari. L'azienda ha rivisto le previsioni per l'intero anno, prevedendo un fatturato compreso tra 2.700 milioni e 2.750 milioni di dollari e un EBITDA rettificato di 220 milioni a 240 milioni di dollari. Il CEO Tom Pike ha espresso fiducia nella direzione dell'azienda, nonostante le sfide, citando progressi con i clienti e importanti nuove opportunità.
Fortrea (Nasdaq: FTRE) reportó sus resultados financieros del segundo trimestre de 2024, mostrando ingresos de 662,4 millones de dólares y una pérdida neta GAAP de 99,3 millones de dólares. El EBITDA ajustado de la empresa fue de 55,2 millones de dólares, con una relación book-to-bill de 0,96x. Fortrea completó la venta de las unidades de negocios de Endpoint Clinical y Patient Access, reduciendo su deuda en 504 millones de dólares. La compañía revisó su guía para todo el año, proyectando ingresos entre 2.700 millones y 2.750 millones de dólares y un EBITDA ajustado de 220 millones a 240 millones de dólares. El CEO Tom Pike expresó confianza en la dirección de la empresa a pesar de los desafíos, citando progresos con los clientes y nuevas oportunidades importantes.
Fortrea (Nasdaq: FTRE)는 2024년 2분기 재무 결과를 발표하였으며, 매출이 6억 6,240만 달러, GAAP 기준 순손실이 9천 930만 달러라고 밝혔습니다. 회사의 조정된 EBITDA는 5천 520만 달러였으며, 주문 대 매출 비율은 0.96배입니다. Fortrea는 Endpoint Clinical 및 Patient Access 사업 부문의 매각을 완료하여 부채를 5억 4천만 달러 줄였습니다. 회사는 연간 가이던스를 수정하여 매출이 27억에서 27억 5천만 달러, 조정된 EBITDA가 2억 2천만에서 2억 4천만 달러 사이가 될 것이라고 전망했습니다. CEO 톰 파이크는 도전 과제가 있음에도 불구하고 회사의 방향에 대한 확신을 표명하며, 고객들과의 진전을 언급하고 중요한 새로운 기회를 인용하였습니다.
Fortrea (Nasdaq: FTRE) a annoncé ses résultats financiers pour le deuxième trimestre 2024, affichant un chiffre d'affaires de 662,4 millions de dollars et une perte nette GAAP de 99,3 millions de dollars. L'EBITDA ajusté de l'entreprise s'élevait à 55,2 millions de dollars, avec un taux book-to-bill de 0,96x. Fortrea a achevé la cession de ses activités Endpoint Clinical et Patient Access, réduisant la dette de 504 millions de dollars. L'entreprise a révisé ses prévisions annuelles, projetant un chiffre d'affaires compris entre 2 700 millions et 2 750 millions de dollars et un EBITDA ajusté de 220 millions à 240 millions de dollars. Le PDG Tom Pike a exprimé sa confiance dans la direction de l'entreprise malgré les défis, citant des progrès avec les clients et d'importantes nouvelles opportunités.
Fortrea (Nasdaq: FTRE) hat seine finanziellen Ergebnisse für das 2. Quartal 2024 veröffentlicht und einen Umsatz von 662,4 Millionen Dollar sowie einen GAAP-Nettoverlust von 99,3 Millionen Dollar gemeldet. Das bereinigte EBITDA des Unternehmens betrug 55,2 Millionen Dollar, mit einem Book-to-Bill-Verhältnis von 0,96x. Fortrea hat die Abgabe der Geschäftsbereiche Endpoint Clinical und Patient Access abgeschlossen und die Schulden um 504 Millionen Dollar reduziert. Das Unternehmen hat seine Jahresprognose überarbeitet und rechnet mit einem Umsatz zwischen 2.700 Millionen und 2.750 Millionen Dollar und einem bereinigten EBITDA von 220 Millionen bis 240 Millionen Dollar. CEO Tom Pike äußerte trotz Herausforderungen Zuversicht in die Richtung des Unternehmens und nannte Fortschritte bei den Kunden sowie wichtige neue Chancen.
- Adjusted EBITDA increased sequentially by 103.7% in the quarter
- Completed divestitures of Endpoint Clinical and Patient Access businesses
- Debt paydown of $504 million using divestiture and securitization proceeds
- Strong backlog of $7.366 billion as of June 30, 2024
- Positive operating cash flow of $248.1 million for the first half of 2024
- Revenue declined from $725.1 million in Q2 2023 to $662.4 million in Q2 2024
- GAAP net loss of $(99.3) million compared to net income of $25.0 million in Q2 2023
- Adjusted EBITDA decreased from $71.9 million in Q2 2023 to $55.2 million in Q2 2024
- Book-to-bill ratio declined to 0.96x for the quarter
- Revised full-year guidance downward for both revenue and adjusted EBITDA
Fortrea's Q2 2024 results paint a mixed picture. Revenue declined
Fortrea's Q2 results reflect ongoing industry challenges in the CRO space. The book-to-bill ratio of 0.96x for the quarter, while slightly below 1, isn't alarming given the 1.16x trailing 12-month figure. However, the lower net new business in H1 2024 is concerning, as it's impacting H2 revenue projections. The company's focus on becoming a pure-play clinical services organization could be strategic long-term, but short-term pain is evident. The divestiture of Endpoint Clinical and Patient Access businesses signals a streamlining of operations. Investors should watch for signs of success in Fortrea's transformation efforts and any improvements in winning new contracts.
Fortrea's ongoing IT systems transition is a critical factor in its performance. The company has exited
For the three months ended June 30, 2024, from continuing operations:
- Revenues of
$662.4 million - GAAP net loss of
$(99.3) million - Adjusted EBITDA of
$55.2 million - GAAP and adjusted diluted loss per share of
$(1.11) and$(0.03) , respectively - Book-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 months
- Completed divestiture of assets relating to the Endpoint Clinical and Patient Access businesses
- Debt paydown of
$504 million in the quarter using initial divestiture and securitization proceeds - Revised full-year guidance
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the second quarter ended June 30, 2024.
“Fortrea continues to make progress with customers and our business, which is not reflected in the headline numbers,” said Tom Pike, chairman and CEO of Fortrea. “We won some important opportunities this quarter. We have increased our focus as an innovative, global pure-play clinical services organization. We have now exited 60 percent of our Transition Services Agreement and are making good progress on the most difficult part, the IT systems, and managing the related one-time costs. We have reduced our debt. We have our margin improvement actions in focus. We are transforming. I’m confident we’re headed in the right direction to deliver value for all our stakeholders, delivering solutions that bring new treatments to patients faster.”
All commentary in this press release relates to continuing operations unless otherwise noted.
Second Quarter 2024 Financial Results
Revenue for the second quarter was
Second quarter GAAP net loss was
Backlog as of June 30, 2024, was
First Half 2024 Financial Results
Revenue for the first half was
First half GAAP net loss was
The Company’s cash and cash equivalents were
Full-Year 2024 Guidance
For the full year 2024, the Company is revising its revenue guidance to a range of
Earnings Call and Replay
Fortrea will host its quarterly conference call on Monday, August 12, 2024, at 9:00 am ET to review its second quarter performance. The conference can be accessed through the Fortrea Investor Relations website or the following earnings webcast link. To avoid potential delays, please join at least 10 minutes prior to the start of the call. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Fortrea Investor Relations website prior to the start of the call.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company’s 2024 financial guidance, exiting the remainder of the Transition Services Agreements and realizing the benefits of our margin improvement actions. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company’s expectations due to a number of factors, including, but not limited to, the following: if the Company does not realize some or all of the benefits expected to result from the spin-off of the Company (the “Spin”) from Laboratory Corporation of America Holdings (“Labcorp”), or if such benefits are delayed; risks and consequences that are a result of the Spin; the impacts of becoming an independent public company; the Company’s reliance on Labcorp to provide financial reporting and other financial and accounting information for periods prior to the Spin through the end of the relevant transition agreements, as well as IT, accounting, finance, legal, human resources, and other services critical to the Company’s businesses; the Company’s dependence on third parties generally to provide services critical to the Company’s businesses throughout the transition period and beyond; the establishment of the Company’s accounting, enterprise resource planning, and other management systems post the transition period, which could cost more or take longer than anticipated; the impact of the rebranding of the Company; the Company’s ability to successfully implement the Company’s business strategies and execute the Company’s long-term value creation strategy; risks and expenses associated with the Company’s international operations and currency fluctuations; the Company’s customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment, which could lead to defaults or cancellations by the Company’s customers; the risk that the Company’s backlog and net new business may not be indicative of the Company’s future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company’s backlog; the Company’s ability to generate sufficient net new business awards, or if net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; the Company’s realize the full benefits from the divestiture of Endpoint Clinical and Fortrea Patient Access businesses; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company’s filings with the SEC. Comparisons of results for current and any prior periods are not intended to express any future, or indications of future performance, unless expressed as such, and should only be viewed as historical data. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.
Note on Non-GAAP Financial Measures
This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Basic and Diluted EPS, and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the Company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the Company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the Company’s results of operations as determined in accordance with GAAP.
The Company uses non-GAAP measures in its operational and financial decision making and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, in calculating Adjusted EBITDA, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although the Company excludes amortization of acquired intangible assets from the Company’s non-GAAP expenses, the Company believes that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to the Company. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The Company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.
The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. The Company’s full-year 2024 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the Company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition-related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the Company's ongoing operations.
Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the Company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the Company’s results of operations as determined in accordance with GAAP.
Fortrea Contacts
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS (in millions, except per share data) (unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues | $ | 662.4 | $ | 725.1 | $ | 1,324.5 | $ | 1,419.0 | |||||||
| Costs and expenses: | |||||||||||||||
| Direct costs, exclusive of depreciation and amortization (including costs incurred from related parties of | 525.3 | 568.7 | 1,079.5 | 1,110.2 | |||||||||||
| Selling, general and administrative expenses, exclusive of depreciation and amortization | 156.2 | 97.8 | 276.3 | 214.6 | |||||||||||
| Depreciation and amortization | 21.4 | 23.4 | 43.3 | 44.3 | |||||||||||
| Restructuring and other charges | 10.4 | 3.6 | 13.7 | 4.2 | |||||||||||
| Total costs and expenses | 713.3 | 693.5 | 1,412.8 | 1,373.3 | |||||||||||
| Operating income (loss) | (50.9 | ) | 31.6 | (88.3 | ) | 45.7 | |||||||||
| Other income (expense): | |||||||||||||||
| Interest expense | (45.2 | ) | (0.7 | ) | (79.5 | ) | (0.6 | ) | |||||||
| Foreign exchange gain (loss) | (1.5 | ) | 5.2 | (6.8 | ) | — | |||||||||
| Other, net | 9.0 | 0.5 | 10.3 | 1.0 | |||||||||||
| Income (loss) from continuing operations before income taxes | (88.6 | ) | 36.6 | (164.3 | ) | 46.1 | |||||||||
| Provision for income taxes | 10.7 | 11.6 | 14.8 | 13.1 | |||||||||||
| Income (loss) from continuing operations | (99.3 | ) | 25.0 | (179.1 | ) | 33.0 | |||||||||
| Income (loss) from discontinued operations, net of tax | (39.1 | ) | 5.8 | (60.3 | ) | 10.3 | |||||||||
| Net income (loss) | $ | (138.4 | ) | $ | 30.8 | $ | (239.4 | ) | $ | 43.3 | |||||
| Earnings (loss) per common share | |||||||||||||||
| Basic earnings (loss) per share continuing operations | $ | (1.11 | ) | $ | 0.28 | $ | (2.01 | ) | $ | 0.37 | |||||
| Basic earnings per share discontinued operations | (0.44 | ) | 0.07 | (0.68 | ) | 0.12 | |||||||||
| Basic earnings (loss) per share | $ | (1.55 | ) | $ | 0.35 | $ | (2.69 | ) | $ | 0.49 | |||||
| Diluted earnings (loss) per share continuing operations | $ | (1.11 | ) | $ | 0.28 | $ | (2.01 | ) | $ | 0.37 | |||||
| Diluted earnings per share discontinued operations | (0.44 | ) | 0.07 | (0.68 | ) | 0.12 | |||||||||
| Diluted earnings (loss) per share | $ | (1.55 | ) | $ | 0.35 | $ | (2.69 | ) | $ | 0.49 | |||||
| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (dollars and shares in millions) (unaudited) | |||||||
| June 30, 2024 | December 31, 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 126.2 | $ | 108.6 | |||
| Accounts receivable and unbilled services, net | 637.9 | 988.5 | |||||
| Prepaid expenses and other | 123.6 | 84.6 | |||||
| Current assets of discontinued operations | — | 69.1 | |||||
| Total current assets | 887.7 | 1,250.8 | |||||
| Property, plant and equipment, net | 173.1 | 172.6 | |||||
| Goodwill, net | 1,725.7 | 1,739.4 | |||||
| Intangible assets, net | 691.9 | 728.1 | |||||
| Deferred income taxes | 3.2 | 3.2 | |||||
| Other assets, net | 83.8 | 69.7 | |||||
| Long-term assets of discontinued operations | — | 368.8 | |||||
| Total assets | $ | 3,565.4 | $ | 4,332.6 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 144.2 | $ | 132.9 | |||
| Accrued expenses and other current liabilities | 343.3 | 335.5 | |||||
| Unearned revenue | 248.0 | 214.2 | |||||
| Current portion of long-term debt | — | 26.1 | |||||
| Short-term operating lease liabilities | 13.5 | 17.2 | |||||
| Current liabilities of discontinued operations | — | 52.5 | |||||
| Total current liabilities | 749.0 | 778.4 | |||||
| Long-term debt, less current portion | 1,123.8 | 1,565.9 | |||||
| Operating lease liabilities | 65.8 | 62.8 | |||||
| Deferred income taxes and other tax liabilities | 136.1 | 147.7 | |||||
| Other liabilities | 29.6 | 32.1 | |||||
| Long-term liabilities of discontinued operations | — | 31.6 | |||||
| Total liabilities | 2,104.3 | 2,618.5 | |||||
| Commitments and contingent liabilities | |||||||
| Equity | |||||||
| Common stock, 89.5 and 88.8 shares outstanding on June 30, 2024, and December 31, 2023, respectively | 0.1 | 0.1 | |||||
| Additional paid-in capital | 2,017.9 | 1,998.0 | |||||
| Accumulated deficit | (307.9 | ) | (68.5 | ) | |||
| Accumulated other comprehensive loss | (249.0 | ) | (215.5 | ) | |||
| Total equity | 1,461.1 | 1,714.1 | |||||
| Total liabilities and equity | $ | 3,565.4 | $ | 4,332.6 | |||
| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (in millions) (unaudited) | |||||||
| Six Months Ended June 30, | |||||||
| 2024 | 2023 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
| Net income (loss) | $ | (239.4 | ) | $ | 43.3 | ||
| Adjustments to reconcile net earnings to net cash provided by (used for) operating activities: | |||||||
| Depreciation and amortization | 44.9 | 48.6 | |||||
| Stock compensation | 30.1 | 16.1 | |||||
| Operating lease right-of-use asset expense | 11.9 | 14.3 | |||||
| Goodwill and other asset impairments | 24.0 | — | |||||
| Deferred income taxes | (11.6 | ) | (4.5 | ) | |||
| Loss on sale of business | 23.2 | — | |||||
| Write-off of debt issuance costs | 12.2 | — | |||||
| Other, net | (7.8 | ) | 6.5 | ||||
| Changes in assets and liabilities: | |||||||
| Decrease in accounts receivable and unbilled services, net | 359.4 | 11.4 | |||||
| Increase in prepaid expenses and other | (11.7 | ) | (17.2 | ) | |||
| Increase in accounts payable | 13.0 | 19.9 | |||||
| Increase (decrease) in deferred revenue | 34.2 | (5.5 | ) | ||||
| (Decrease) increase in accrued expenses and other | (34.3 | ) | 15.2 | ||||
| Net cash provided by operating activities | 248.1 | 148.1 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
| Capital expenditures | (20.5 | ) | (25.8 | ) | |||
| Proceeds from sale of business, net | 276.6 | — | |||||
| Proceeds from sale of assets | 0.1 | 0.3 | |||||
| Net cash provided by (used for) investing activities | 256.2 | (25.5 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
| Proceeds from revolving credit facilities | 474.5 | — | |||||
| Payments on revolving credit facilities | (474.5 | ) | — | ||||
| Proceeds from term loans | — | 1,061.4 | |||||
| Proceeds from issuance of senior notes | — | 570.0 | |||||
| Debt issuance costs | — | (26.4 | ) | ||||
| Principal payments of long-term debt | (482.7 | ) | — | ||||
| Special payment to Former Parent | — | (1,595.0 | ) | ||||
| Net transfers (to) Former Parent | — | (135.4 | ) | ||||
| Net cash used for financing activities | (482.7 | ) | (125.4 | ) | |||
| Effect of exchange rate changes on cash and cash equivalents | (4.0 | ) | 1.3 | ||||
| Net change in cash and cash equivalents | 17.6 | (1.5 | ) | ||||
| Cash and cash equivalents at beginning of period | 108.6 | 110.4 | |||||
| Cash and cash equivalents at end of period | $ | 126.2 | $ | 108.9 | |||
The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated and combined statements of cash flows.
| RECONCILIATION OF NON-GAAP MEASURES FORTREA HOLDINGS INC. | |||||||||||||||||||||
| NET INCOME TO ADJUSTED EBITDA RECONCILIATION (in millions) (unaudited) | |||||||||||||||||||||
| Trailing Twelve Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2024 | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||
| Adjusted EBITDA from Continuing Operations: | |||||||||||||||||||||
| Net income (loss) from continuing operations | $ | (243.8 | ) | $ | (99.3 | ) | $ | 25.0 | $ | (179.1 | ) | $ | 33.0 | ||||||||
| Provision for income taxes | 2.9 | 10.7 | 11.6 | 14.8 | 13.1 | ||||||||||||||||
| Interest expense, net | 148.6 | 45.2 | 0.7 | 79.5 | 0.6 | ||||||||||||||||
| Foreign exchange (gain) loss | 6.5 | 1.5 | (5.2 | ) | 6.8 | — | |||||||||||||||
| Depreciation and amortization (a) | 88.3 | 21.4 | 23.4 | 43.3 | 44.3 | ||||||||||||||||
| Restructuring and other charges (b) | 34.0 | 11.0 | 3.6 | 14.4 | 4.2 | ||||||||||||||||
| Stock based compensation | 54.2 | 15.4 | 8.8 | 28.9 | 15.1 | ||||||||||||||||
| Disposition-related costs (c) | 1.4 | 1.4 | — | 1.4 | — | ||||||||||||||||
| One-time spin related costs (d) | 102.2 | 53.9 | — | 70.9 | — | ||||||||||||||||
| Customer matter (e) | 13.0 | 0.4 | — | 4.3 | — | ||||||||||||||||
| Enabling Services Segment costs not included in discontinued operations (f) | 17.8 | 2.5 | 4.2 | 7.3 | 8.7 | ||||||||||||||||
| Other (g) | (15.7 | ) | (8.9 | ) | (0.2 | ) | (10.2 | ) | (0.3 | ) | |||||||||||
| Adjusted EBITDA from Continuing Operations | $ | 209.4 | $ | 55.2 | $ | 71.9 | $ | 82.3 | $ | 118.7 | |||||||||||
(a) Amortization represents amortization of intangible assets acquired as part of business acquisitions.
(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions to reduce overcapacity, align resources and restructure certain operations.
(c) Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.
(d) Represents one-time or incremental costs required to implement capabilities to exit the Transition Services Agreement with former parent.
(e) As part of working with a customer, the Company has agreed to make concessions and provide discounts and other consideration to the customer as part of a multi-party solution.
(f) These adjustments remove the impact of the Enabling Services Segment, which the Company sold in the second quarter of 2024.
(g) Includes the recognition of a contingent consideration payment on a sale of a facility recorded in the second quarter of 2024 and income related to services provided under the Transition Services Agreements.
| FORTREA HOLDINGS INC. | ||||||||||||||||
| NET INCOME TO ADJUSTED NET INCOME RECONCILIATION (dollars and shares in millions, except per share data) (unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Adjusted net income (loss) from continuing operations : | ||||||||||||||||
| Net income (loss) | $ | (99.3 | ) | $ | 25.0 | $ | (179.1 | ) | $ | 33.0 | ||||||
| Foreign exchange (gain)/loss | 1.5 | (5.2 | ) | 6.8 | — | |||||||||||
| Amortization (a) | 15.1 | 15.4 | 30.4 | 30.4 | ||||||||||||
| Restructuring and other charges (b) | 11.0 | 3.6 | 14.4 | 4.2 | ||||||||||||
| Stock based compensation | 15.4 | 8.8 | 28.9 | 15.1 | ||||||||||||
| Disposition-related costs (c) | 1.4 | — | 1.4 | — | ||||||||||||
| One-time spin related costs (d) | 53.9 | — | 70.9 | — | ||||||||||||
| Customer matter (e) | 0.4 | — | 4.3 | — | ||||||||||||
| Enabling Services Segment costs not included in discontinued operations (f) | 2.5 | 4.2 | 7.3 | 8.7 | ||||||||||||
| Other (g) | (8.9 | ) | (0.2 | ) | (10.2 | ) | (0.3 | ) | ||||||||
| Income tax impact of adjustments (h) | 4.7 | (5.5 | ) | 17.7 | (12.0 | ) | ||||||||||
| Adjusted net income (loss) from continuing operations | $ | (2.3 | ) | $ | 46.1 | $ | (7.2 | ) | $ | 79.1 | ||||||
| Basic shares | 89.4 | 88.8 | 89.3 | 88.8 | ||||||||||||
| Diluted shares | 89.4 | 88.8 | 89.3 | 88.8 | ||||||||||||
| Adjusted basic EPS from continuing operations | $ | (0.03 | ) | $ | 0.52 | $ | (0.08 | ) | $ | 0.89 | ||||||
| Adjusted diluted EPS from continuing operations | $ | (0.03 | ) | $ | 0.52 | $ | (0.08 | ) | $ | 0.89 | ||||||
(a) Represents amortization of intangible assets acquired as part of business acquisitions.
(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions to reduce overcapacity, align resources, and restructure certain operations.
(c) Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.
(d) Represents one-time or incremental costs required to implement capabilities to exit the Transition Services Agreement with former parent.
(e) As part of working with a customer, the Company has agreed to make concessions and provide discounts and other consideration to the customer as part of a multi-party solution.
(f) These adjustments remove the impact of the Enabling Services Segment, which the Company sold in the second quarter of 2024.
(g) Includes the recognition of a contingent consideration payment on a sale of a facility recorded in the second quarter of 2024 and income related to services provided under the Transition Services Agreements.
(h) Income tax impact of adjustments calculated based on the tax rate applicable to each item.
| FORTREA HOLDINGS INC. NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION (in millions) (unaudited) | ||||
| Six Months Ended June 30, 2024 | ||||
| Net cash provided by operating activities | $ | 248.1 | ||
| Capital expenditures | (20.5 | ) | ||
| Free cash flow | $ | 227.6 | ||
The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated and combined statements of cash flows.
FAQ
What was Fortrea's revenue for Q2 2024?
How did Fortrea's Q2 2024 results compare to Q2 2023?
What is Fortrea's revised full-year 2024 revenue guidance?
How much debt did Fortrea (FTRE) pay down in Q2 2024?
What was Fortrea's (FTRE) book-to-bill ratio for Q2 2024?
